PubMed HealthSearch

PubMed · 8677256

Managed care: managed change.

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B A Hochstadt. 1995. Managed care: managed change.. https://pubmed.ncbi.nlm.nih.gov/8677256/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

[Medical support for the Armed Forces: the results and the outlook].

A discussion of actual problems in the medical maintenance of the Armed Forces of Russia--combat and deployment readiness of the medical service, its personnel training programmes, sanitary-epidemiological control, medical treatment and prophylactics, medical materiel research and development for troops health care. The article deals with the military medical service' tasks of 1999 and of the imminent future focusing on the medical specialists' education with a due regard for their stationing and a possibility of substitution of military medical officers by civilians and the formation of an overall Armed Forces medical maintenance system on a territorial basis.

Diagnostic Services

Molecular pathology and managed care: challenges and opportunities.

The inherent costs of sophisticated molecular-based diagnostic tests are of significant importance to managed care organizations. Providers of molecular diagnostic services have emphasized that these tests can provide a reduced length of stay for hospitalized patients resulting from earlier definitive diagnosis, a reduction in the use of less expensive nondefinitive tests, a reduction in expensive ancillary diagnostic services such as radiologic imaging and endoscopies, an enhanced ability to predict disease outcome and responses to various expensive therapies, and new programs in detecting disease risk and maintaining patient wellness. In order for these newer molecular-based tests to be included in the list of covered services by the health maintenance organizations (HMOs), the clinical value and potential cost-benefit ratios must be articulated to the medical directors, administrative officials, and subscribers of the HMOs by the molecular diagnostic test providers.

Diagnostic Services